Cite
HARVARD Citation
Sahdev, I. et al. (2020). Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease. Journal of pediatric hematology/oncology. 42 (8), p. . [Online].